Bosutris 500 Tablet
By Bosutris
Rx
30 Tablet in a Bottle

Composition
Bosutinib(500mg)

Manufacturer - Mylan Pharmaceuticals Pvt Ltd
Mylan Pharmaceuticals Private Limited , Commercial Operations , Prestige Tech Park,Platina-3, 7th to 12th floor, Prestige Tech Park, Kadubesanahalli, Bangalore -560103

Expires on or after
July, 2025

liver
When taking Bosutris 500 Tablet, it is important to be cautious if you have liver disease. This medication may require a dosage adjustment for patients with liver issues. It is crucial to consult your doctor before using Bosutris 500 Tablet if you have a history of liver disease or any pre-existing liver conditions. Bosutris 500 Tablet has the potential to cause liver damage, so it is essential to keep your healthcare provider informed about your liver health.

kidney
Bosutris 500 Tablet may require dose adjustment for patients with kidney disease. Inform your doctor if you have kidney issues before taking this medication. Your doctor may adjust the dose or recommend an alternative. Consult your doctor for guidance.

alcohol
It is advised to avoid consuming alcohol while taking Bosutris 500 Tablet to prevent potential serious adverse effects. Consult your doctor regarding alcohol consumption while on this treatment.

driving
Bosutris 500 Tablet may cause dizziness and drowsiness. Do not drive if you feel these symptoms until you are alert. If any symptoms affect your concentration or reaction, avoid driving.

pregnancy
Bosutris 500 Tablet is not safe to use during pregnancy due to known risks to the baby's development. In rare life-threatening cases, a doctor may still recommend it if the benefits are greater. Always consult your doctor if you are pregnant or planning pregnancy before taking Bosutris 500 Tablet.

breastfeeding
Bosutris 500 Tablet may not be safe during breastfeeding as it could pass into breastmilk and harm the baby. Limited data is available, so it's advised to avoid using Bosutris 500 Tablet while breastfeeding. Please consult your doctor for guidance.
Habit Forming | No |
Chemical Class | 4-aminoquinolines |
Therapeutic Class | - |
Action Class | Tyrosine kinase inhibitors |
₹11000
Inclusive of all taxes
Content verified by

Dr. Monie Riju Simon
MBBS - General Medicine
Last update on 11-Feb-2025